Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats

Journal of Surgical Research

Volumn 69, Issue 2, 1997, Pages 393-398

  Kakkis, Jane L ^a   Ke, B ^a   Dawson, S ^a   Maggard, M ^a   Si, M ^a   Kaldas, F ^a   Cai, W ^a   Shau, H ^a   Seu, P ^a   Sauri, H ^b   Busuttil, R W ^a   Imagawa, D K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DENSITOMETRY; GENE EXPRESSION REGULATION; GRAFT REJECTION; IMMUNE RESPONSE; LIVER FIBROSIS; LIVER TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RADIOGRAPHY; RAT; SURVIVAL;

EID: 0031148478     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5107     Document Type: Conference Paper

References (23)

1. 1. Ellison, M. D., Daily, O. P., and Kauffman, M. (Eds.) Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network. U.S. Department of Health and Human Services, 1994.
2. 2. Weisner, R. H., Ludwig, J., Van Hoek, B., and Krom, R. A. F. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 14: 721, 1991.
3. 3. Kobashigawa, J. A., Naftel, D. C., Bourge, R. C., et al. Pretransplantation risk factors for acute rejection after heart transplantation: A multiinstitutional study. J. Heart Lung Transplant. 12: 35,1993.
4. 4. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269: 3015, 1993.
5. 5. Brown, G., Albers, J. J., Fisher, L. D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323: 1289, 1990.
6. 6. Kane, J. P., Malloy, M. J., Ports, T. A., Phillips, N. R., Diehl, J. C., and Havel, R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007, 1990.
7. 7. Blankenhorn, D. H., and Hodis, H. N. Atherosclerosis - Reversal with therapy. West. J. Med. 159: 172, 1993.
8. 8. Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J., Yeatman, L., Wang, X., et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333(10): 621, 1995.
9. 9. Katznelson, S., Wilkinson, A. H., Kobashigawa, J. A., Wang, X. M., Shia, D., Ozawa, M., Zhong, H. P., Hirata, M., Cohen, A. H., Terasaki, P., et al. The effect of pravastatin on acute rejection after kidney transplantation - A pilot study. Transplantation 61(10): 1469, 1996.
10. 10. McPherson, R., Tsoukas, C., Baines, M. G., et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J. Clin. Immunol. 13: 439, 1993.
11. 11. Kruezer, J., Bader, J., Jahn, L., Hautmann, M., Kubler, W., and Von Hodenberg, E. Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 90: 203, 1991.
12. 12. Cutts, J. L., Scallen, T. J., Watson, J., and Bankhurst, A. D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell Physiol. 139: 550, 1990.
13. 13. Kamada, N. Experimental Liver Transplantation. Boca Raton, FL: CRC Press, 1988.
14. 14. Sambrook, J., Fritsch, E., and Maniatis, T. Molecular Cloning, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989. Pp. 7.39-52, 7.6-18, 18.18-26.
15. 15. Regazzi, M. B., Iacona, I., Campana, C., Gavazzi, A., Vigano, M., and Perani, G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A. Transplant. Proc. 26(5): 2644, 1994.
16. 16. Imagawa, D. K., Dawson, S., Holt, C., Kirk, P., Kaldas, F., and Shackleton, C. R., et al. Hyperlipidemia after liver transplantation. Transplantation 62(7), 1996.
17. 17. Sauri, H., Butterfield, L., Kim, A., and Shau, H. Antioxidant function of recombinant human natural killer enhancing factor. Biochem. Biophys. Res. Commun. 208(3): 964, 1995.
18. 18. Shau, H., and Kim, A. Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. Biochem. Biophys. Res. Commun. 199(1): 83, 1994.
19. 19. Shau, H., Roth, M., and Golub, S. H. Regulation of natural killer function by nonlymphoid cells. Nat. Immun. 12: 235, 1993.
20. 20. Kiessling, R., Hochman, P. S., Hallor, O., Shearer, G. M., and Wigzel, H. Evidence for a similar or common mechanism for natural killer cell activity and resistance to haemopoietic grafts. Eur. J. Immunol. 7: 655, 1977.
21. 21. Nemlander, A., Saksela, E., and Hayry, P. Are "natural killer" cells involved in allograft rejection? Eur. J. Immunol. 13: 348, 1983.
22. 22. Zhao, D., Zimmermann, A., Kuznetsova, L., and Wheatley, A. Regression of bile duct damage and bile duct proliferation in the non-rearterialized transplanted rat liver is associated with spontaneous graft rearterialization. Hepatology 21:1353, 1995.
23. 23. Zhao, D., Zimmermann, A., and Wheatley, A. Morphometry of the liver after liver transplantation in the rat: Significance of an intact arterial supply. Hepatology 17: 310, 1993.